Overview of Transforming Growth Factor β Superfamily Involvement in Glioblastoma Initiation and Progression

André Wendindondé Nana, Pei-Ming Yang*, Hung-Yun Lin

Abstract

Glioblastoma, also known as glioblastoma multiforme (GBM), is one of the most common and most aggressive types of malignant brain tumors, virtually without efficient therapy (Jazayeri et al., 2013; Mrugala, 2013; Ostrom et al., 2014b). It belongs to the most malignant form of astrocytoma, grade IV, along with gliosarcoma and giant cell glioblastoma (Louis et al., 2007). Histologically, GBM usually displays small areas of necrotic tissue surrounded by anaplastic cells, as well as hyperplastic blood vessels (Nakada et al., 2011). Its incidence ranges from 0.59 to 3.69 per 100,000 persons and it occurs more commonly in men than in women (Ostrom et al., 2014a). The lack of effective therapy for GBM is due to the remarkable histological variations as different GBM subtypes can be found within the same tumor sample, to the blood-brain barrier and blood-tumor brain barrier that constitute obstacles to drug delivery and to its resistance to existing therapies, especially temozolomide, its main pharmacological approach (Sottoriva et al., 2013; Messaoudi et al., 2015; van Tellingen et al., 2015).

The transforming growth factor β (TGFβ) superfamily is a large group of structurally related proteins including TGFβ subfamily members Nodal, Activin, Lefty, bone morphogenetic proteins (BMPs) and growth and differentiation factor (GDF). It is involved in important biological functions including morphogenesis, embryonic development, adult stem cell differentiation, immune regulation, wound healing and inflammation. This superfamily is also considered to impact on cancer biology including that of GBM, with various effects depending on the member. The TGFβ subfamily, in particular, is overexpressed in some GBM types which exhibit aggressive phenotypes. This subfamily impairs anti-cancer immune responses in several ways, including immune cells inhibition and major histocompatibility (MHC) class I and II abolishment. It promotes GBM angiogenesis by inducing angiogenic factors such as vascular endothelial growth factor (VEGF), plasminogen activator inhibitor (PAI-I) and insulin-like growth factor-binding protein 7 (IGFBP7), contributes to GBM progression by inducing metalloproteinases (MMPs), “pro-neoplastic” integrins (αvβ3, α5β1) and GBM initiating cells (GICs) as well as inducing a GBM mesenchymal phenotype. Equally, Nodal promotes GICs, induces cancer metabolic switch and supports GBM cell proliferation, but is negatively regulated by Lefty. Activin promotes GBM cell proliferation while GDF yields immune-escape function. On the other hand, BMPs target GICS and induce differentiation and sensitivity to chemotherapy. This multifaceted involvement of this superfamily in GBM necessitates different strategies in anti-cancer therapy. While suppressing the TGFβ subfamily yields advantageous results, enhancing BMPs production is also beneficial.

Keywords: Glioblastoma - transforming growth factor β (TGFβ) superfamily - anti-TGFβ drugs
Concomitantly, evidence shows an obvious implication of growth factors in some aggressive phenotypes (Rodon et al., 2014). GBM is complex and heterogeneous with regard to its cellular and molecular structure, and tumor cells interact with each other and their microenvironment via the secretion of chemokines, cytokines and growth factors in a complicated network (Bonavia et al., 2011). Nakada et al. described the overexpression of growth factors as the second main event in GBM’s biology (Nakada et al., 2011). These growth factors diverted from their physiological roles, will yield aberrant signaling within the tumor cells to drive the tumor growth and metastasis, leading to a poor outcome for the patient. As a result, these growth factors and the signaling pathways they induce are continuously under intense investigation to detect possible therapeutic targets.

The TGFβ superfamily is involved in important biological functions including morphogenesis, embryonic development, adult stem cell differentiation, immune regulation, wound healing and inflammation (Santibanez et al., 2011). This superfamily is a large group of structurally related proteins that counts over 30 members in humans, divided into two branches: (1) the transforming growth factor-like (TGF-like) group with the TGFβ subfamily, Activin, Nodal and some growth and differentiation factors (GDF), and (2) the bone morphogenetic protein-like (BMP-like) group with the BMP, GDF and anti-Mullerian hormone (AMH) (Weiss and Attisano, 2013). However, this protein family is implicated in the biology of various cancers including GBM, with variable effects. Some members notably the TGFβ subfamily, Activin, Nodal and GDF contribute to carcinogenesis or render tumors more aggressive, while BMP and Lefty, the antagonist of Nodal, have a tumor suppression effect. Here we provide an overview of the role of this superfamily in GBM biology, with a particular focus on the TGFβ subfamily whose implication is prominent.

Classification of Glioblastoma

The complexity of the mechanisms involved in the biology of GBM testifies to the multitude of classifications of this disease. GBM can be classified according to its mode of occurrence. In this regard, GBM can result from the progression of more benign brain tumors (secondary type) or can occur de novo (primary type). The latter is the most common form (Ohgaki and Kleihues, 2009). In addition, The World Health Organization made a classification of all brain tumors, based on the histological origin, to retrieve a clinical and prognostic significance, ranking GBM within the highest grade (grade V) (Louis et al., 2007). GBM presents a particular heterogeneity and displays tremendous genetic and epigenetic aberrations as evidenced by the results of The Cancer Genome Atlas Research Network’s study (The Cancer Genome Atlas Research Network, 2008). A classification based on gene expression profile distinguishes a classical subtype, a mesenchymal subtype, a proneural subtype and a neural subtype (Verhaak et al., 2010). The classical subtype displays an abnormally high mutation rate of epidermal growth factor receptor (EGFR), no mutation of TP53 and better survival. The mesenchymal subgroup presents the most frequent mutations in the tumor suppressor NF1, frequent mutations in PTEN and TP53 and significant increase in survival after aggressive treatment. The proneural subtype contains the highest mutation in TP53, PDGFRA and IDH1 genes, and affects a younger population. The last phenotype, the neural subgroup displays several gene mutations at an average rate. This subtype occurs more often in older populations (Verhaak et al., 2010). Furthermore, a categorization of GBM based on frequent signaling pathway alteration individualizes three core pathways with key mutations: the RB pathway (CDKN2A/CDKN2C deletion, RB1 mutation, CDK4/6 amplification), the p53 pathway (CDKN2A deletion/TP53 mutation, MDM1/4 amplification) and the receptor tyrosine kinase (RTK) pathway (Ostrom et al., 2014a). The latter pathway illuminates the particular role played by growth factors receptors mutations.

Growth Factors and Glioblastoma

In multicellular organisms, tissue homeostasis requires a constant communication between cells. Cells receive vital signals within themselves and from their immediate or distant environment that determine their fate by inducing proliferation, differentiation or death (Witsch et al., 2010). A signal-emitting cell releases a growth factor that binds to the corresponding receptor on a signal-receiving cell, to trigger a cascade of downstream events in specific pathways, leading to a cellular response, for example the expression of target genes. Because cell signaling pathways govern vital cellular processes, their disruption or hijacking is a common feature in cancer which promotes aberrant proliferation, tumor survival and ability for metastasis (Hanahan and Weinberg, 2011). Several growth factors are overexpressed in GBM, either by the tumor microenvironment or by the tumor cells. Tumor cells usually express both the growth factors and their receptors, realizing an autocrine loop (Nakada et al., 2011).

Transforming Growth Factors β (TGFβ) Subfamily in Glioblastoma

The signaling pathways of TGFβ subfamily

The TGFβ subfamily is a set of pleiotropic cytokines that regulate cell proliferation, differentiation and extracellular matrix production (Kaminska et al., 2013). It is composed of three isoforms (TGFβ1, TGFβ2 and TGFβ3), coded by three different genes (TGFβI (19q13), TGFβII (1q41) and TGFβIII (14q24)). TGFβ is synthesized initially as an inactive form called pre-pro-TGFβ. Upon proteolysis, which proceeds in the rough endoplasmic reticulum, the pro-TGFβ is released to form a homodimer with another pro-TGFβ via disulfide bonds. Furin, a proprotein convertase, cleaves this homodimer, and drives the formation of the small latent TGFβ complex (SLC) that comprises the mature TGFβ non-covalently bound to the latency-associated protein (LAP) (Annes et al., 2003). The LAP covers the active site of TGFβ, rendering it inactive until the fulfillment...
of certain physiological conditions. Activation of TGFβ can be processed by reactive oxygen species (ROS), mechanical stress induced by the extracellular matrix elasticity, thrombospondin-1, integrins, plasmin and several metalloproteinases (Horiguchi et al., 2012). The SLC can covalently bind to the latent transforming growth factor-β binding protein (LTBP) to form the large latent TGFβ complex (LLC). The latter is the most common secreted form of TGFβ (Ten Dijke and Arthur, 2007). The LTBP plays a key role in the regulation of the active TGFβ availability (Rifkin, 2005). The released mature TGFβ is a dimer that binds to its specific membrane receptor to trigger an intracellular signaling pathway (Dubois et al., 1995).

TGFβ receptors (TβRs) belong to the serine/threonine family of membrane receptors (Massague et al., 1992). The ligand binds to a type II TGFβ receptor (TβRII) that forms a complex with a type I TGFβ receptor (TβRI). This leads to the phosphorylation of the downstream effectors SMAD2 or SMAD3 also called receptor-regulated SMADs (R-SMADs). R-SMADs’ phosphorylation is mediated by the SMAD anchor for receptor activation (SARA) (Tsukazaki et al., 1998). Phosphorylated R-SMADs bind to SMAD4, the common mediator SMAD (Co-SMAD). The R-SMAD-Co-SMAD complex translocates into the nucleus where it triggers the target gene expression in collaboration with other cofactors (Wrana, 1998). These SMAD cofactors vary according to the cellular context and contribute to the context-dependent feature of TGFβ’s pathway (Massague, 2012). This SMAD-dependent signaling accounts for the canonical TGFβ pathway that can be repressed by several regulators. For instance, SMAD6 and SMAD7, also termed inhibitory SMADs (I-SMADs), prevent R-SMADs’ phosphorylation or their association with Co-SMAD (Miyazono, 2000). Also, SMAD ubiquitylation regulatory factors (SMURF1 and SMURF2) can target TβRI for ubiquitination, leading to its proteosomal degradation while c-Ski and SnoN are transcriptional co-repressors that can inhibit the basal expression of TGFβ response genes via binding to the

<table>
<thead>
<tr>
<th>Nature</th>
<th>Substance</th>
<th>Target</th>
<th>Mechanism</th>
<th>Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specific antisense oligodeoxynucleotide</td>
<td>Trabedersen</td>
<td>TGFβ2</td>
<td>Represses TGFβ mRNA translation</td>
<td>- In a phase I/II clinical trial, Trabedersen showed prolonged survival of patients and two cases of long-lasting complete tumor remissions (Hau et al., 2007).</td>
</tr>
<tr>
<td>Small Molecule</td>
<td>Cilengitide</td>
<td>Integrins αvβ3 and αvβ5</td>
<td>Inhibits integrins αvβ3, αvβ5</td>
<td>- In an orthotopic rat xenograft model, Cilengitide potentiated radiotherapy effects (Mikkelsen et al., 2009).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SMAD2</td>
<td>Dephosphorylates SMAD2</td>
<td>- Cilengitide combined to temozolomide chemoradiotherapy failed to improve outcome of newly diagnosed GBM patients with MGMT methylation in a phase III clinical trial (Reardon et al., 2008).</td>
</tr>
<tr>
<td></td>
<td>Galunisertib</td>
<td>TβR</td>
<td>Inhibits TβR</td>
<td>- Galunisertib is under investigation in a phase I clinical trial (NCT02423343) in patients with solid tumors including recurrent glioma, non-small cell lung cancer, and recurrent hepatocellular carcinoma.</td>
</tr>
<tr>
<td>Humanized monoclonal antibody</td>
<td>Fresolimumab</td>
<td>All TGFβ isoforms</td>
<td>Neutralizes circulating TGFβ ligands</td>
<td>- A phase Ib/IIa study combining galunisertib with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma is ongoing under NCT01220271.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- An ongoing phase II clinical trial (NCT01582269) is trying to assess the efficacy of galunisertib alone vs lomustine or galunisertib combined with lomustine in recurrent GBM.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Positron emission tomography (PET) using 89Zr-fresolimumab displayed a good uptake of fresolimumab by high grade glioma cells, although without clinical outcome (den Hollander et al., 2015).</td>
</tr>
</tbody>
</table>
SMAD-response element (Kaminska et al., 2013). Always in the register of the negative regulators, BMP and Activin membrane-bound inhibitor (BAMBI) makes a stable association with the receptors of the TGFβ superfamily in order to inhibit TGFβ along with BMP (Onichtchouk et al., 1999).

Besides this canonical pathway, TGFβ can trigger Smad-independent signaling including mitogen-activated protein kinase (MAPK) pathways, Rho-like GTPase, p58, JNK-MAPK signaling pathways as well as phosphatidyl-inositol-3-kinase (PI3K)/AKT pathways (Mu et al., 2012).

**TGFβ subfamily in glioblastoma biology**

In physiological conditions and early tumor stage, TGFβ has a tumor suppressor activity via its negative growth-regulatory effect. The SMAD2/3-SMAD4 complex inhibits the mitogen c-Myc mRNA and protein expression and the inhibitor of DNA binding 1 and 3 (ID1 and ID3) (Siegel and Massague, 2003) while inducing the cyclin dependent kinase inhibitors p21WAF1/CIP1 and p15INK4b (Alexandrow and Moses, 1995). This joint action leads to the cell cycle arrest at G0/G1 phase. The induction of p15INK4b is SMAD3-dependent. Indeed, TGFβ fails to induce p15INK4b and to inhibit astrocytic growth in Smad3-null mice compared to the wild-type (Rich et al., 1999). The induction of p21WAF1/CIP1 by the SMAD3/SMAD4 complex requires Foxo as a co-factor, which is negatively controlled by the growth-promoting PI3K pathway as well as the telencephalic development factor FoxG1 (Seoane et al., 2004). TGFβ can inhibit glioma cell growth and enhance Fas-mediated apoptosis in vivo (Ashley et al., 1998; Pan et al., 2006).

However, this growth regulatory function is circumvented, moreover overturned in a tumor-promoting way in advanced cancers (Kaminska et al., 2013).

**Alterations of TGFβ subfamily signaling in glioblastoma**

TGFβ’s pathway can be altered in several ways. Indeed, high level of TGFβ is a common feature of this tumor, making its pathway a valuable target for drug discovery (Rodon et al., 2014). Some studies demonstrated an increase of both TGFβ receptors and ligands (Yamada et al., 1995). The SMAD proteins, downstream effectors can also be affected. However, the disturbance observed at this level is still unclear, as several studies showed contradictory results. Indeed, Zhang et al. showed a decrease of R-SMADs and the impairment of their phosphorylation and nuclear translocation upon administration of TGFβ1 to glioma cell lines. This phenomenon seemed associated with the ability of GBM to avoid the growth inhibition effect of TGFβ (Zhang et al., 2006). In contrast, other studies associated high levels of SMADs with greater malignancy and poor prognosis (Bruna et al., 2007; Rodon et al., 2014). Dieterich et al. described an increase of R-SMAD/Co-SMADs complexes in GBM endothelial cells, consistent with the angiogenesis induced by TGFβ (Dieterich et al., 2012). These apparently contradictory findings underline the complexity of the mechanism by which TGFβ pathway is hijacked in GBM.

### Immune suppression by TGFβ subfamily

In physiological conditions, TGFβ is an immune modulator (Travis and Sheppard, 2014). Along with the T regulatory (Treg) cells that it induces, TGFβ inhibits inflammation and prevents adverse effects of self-reactive T cells (Shull et al., 1992; Kulkarni et al., 1993; Wan and Flavell, 2007). TGFβ regulates both innate and adaptive immune systems (Shull et al., 1992; Yang et al., 1999).

The brain is an immune-privileged organ (Bechmann and Woodroofe, 2014). This immune privilege includes, but is not only limited to the presence of the blood-brain barrier, the lack of draining lymphatics, a dearth of professional antigen-presenting cells (APCs), such as dendritic cells (DCs), low expression levels of major histocompatibility complex (MHC) molecules; and many anti-inflammatory soluble modulators (Harris et al., 2014). Notwithstanding this immune privilege, the brain is the theater of immunological battle during the neoplastic process. Thus, high infiltration of Treg cells has a positive correlation with the grade of the tumor (Jacobs et al., 2010). GBM leverages the immune suppressor potential of Treg cells and their partner-cytokine TGFβ. Indeed, TGFβ can inhibit the expression of the MHC classes I and II, in glioma cells. This allows tumor cells to evade surrounding tissues in ‘stealth mode’, undetected by the immune cells (Zagzag et al., 2005). Liang et al. recently demonstrated that a subset of Treg cells, the IL-17+ Tregs, utilize TGFβ to inactivate the antitumor CD8+ T cells (Liang et al., 2014). Ultimately, TGFβ can have an immunosuppressive effect on virtually all infiltrated immune cells including the inhibition of macrophages’ activation, inhibition of T lymphocytes’ and natural killer cells’ maturation, differentiation or functions (Kaminska et al., 2013; Travis and Sheppard, 2014). Conversely, TGFβ’s inhibition restores the infiltration of the tumor by immune cells and enhances pro-inflammatory cytokine production in the brain (Uhl et al., 2004).
TGFβ subfamily promotes angiogenesis

Angiogenesis is a hallmark of cancer, as proper blood supply is vital for tumor growth (Hanahan and Weinberg, 2011). In GBM, TGFβ can induce both the key angiogenic factor, vascular endothelial growth factor (VEGF) and plasminogen activator inhibitor (PAI-1) involved in the maturation of blood vessels (Sanchez-Elsner et al., 2001; Goumans et al., 2002). Likewise, the gene expression pattern in GBM new vessels testifies to the importance of TGFβ-driven angiogenesis. Dietrich et al. characterized the transcriptome profile in GBM new vessels and identified 95 genes differentially expressed. An enrichment in SMADs’ target genes was observed, including COL1A2 and COL3A1 involved in extracellular matrix (ECM) organization, and FN1 implicated in wound healing (Dietrich et al., 2012). Furthermore, insulin-like growth factor-binding protein 7 (IGFBP7) is an insulin growth factor carrier that is strongly expressed in tumor endothelial cells and vascular basement membrane. IGFBP7 is considered as a biomarker of GBM tumor vessel and can be targeted by a specific antibody for molecular imaging (Iqbal et al., 2010). IGFBP7 has pro-angiogenic properties and the IGFBP family elsewhere is incriminated in oncogenesis (Baxter, 2014). IGFBP7 is described to induce the formation of an extensive network of capillary-like tubes of human brain endothelial cells, consecutive to TGFβ administration. This upregulation of IGFBP7 by TGFβ requires ALK/SMAD2 pathway’s activation (Pen et al., 2008). This in vitro finding suggests that TGFβ may utilize IGFBP7 which is abundantly expressed in GBM vessels, to promote tumor vessels formation.

TGFβ subfamily promotes tumor invasion

GBM is a highly invasive tumor (Mrugala, 2013). Invasion of tumor cells into the surrounding tissue is a complex process that requires modifications in cell-cell contacts, cell-matrix contacts and degradation of the local ECM by proteases such as membrane metalloproteinases (MMPs) (Luwor et al., 2008). Integrins are cell adhesion molecules that are also membrane receptors (Bergh et al., 2005). They mediate interactions between cells and ECM, facilitate ECM-dependent organization of the cytoskeleton and activate intracellular signaling required for the regulation of cell adhesion and migration (D’Abaco and Kaye, 2007). Integrin’s role in tumor progression has been well established. Tumor cells commonly reorganize integrins at their surface by repressing “anti-neoplastic” integrins, such as α2β1 and α3β1, while they promote the “pro-neoplastic” ones, including αvβ3, αvβ6, α5β1 or α6β4 (Guo and Giancotti, 2004; Schaffner et al., 2013). The integrins can activate TGFβ by inducing the release of the LAP (Horiguchi et al., 2012). Reciprocally, in several cancers, TGFβ promotes tumor progression and metastasis by increasing integrin’s expression (Heino and Massague, 1989; Fong et al., 2009). Indeed, on glioma cells, TGF-β enhances integrin αvβ3’s expression to promote tumor migration; this effect is inhibited by echistatin, the Arg-Gly-Asp (RGD) peptide antagonist of αvβ3 integrin (Platten et al., 2000). Also, GBM cells expressing high level of α5β1 integrin display aggressive...
cancer cells including GBM. ID1 can be induced by TGFβ (Goumans et al., 2002) to promote tumor progression. Conversely, TGFβ’s inhibition in GICs expressing high levels of ID1 decreased these cells’ population concomitantly as it reduced ID1 and ID3 expression (Anido et al., 2010). TGFβ-mediated actions on GICs may depend on the GBM subtype. Indeed, GICs of the proneural subtype, while less responsive to TGFβ’s action, secrete TGFβ and utilize TGFβ immunosuppressive ability to reduce the infiltration of immune cells. On the other hand, GICs of the mesenchymal subtype seem more sensitive to TGFβ’s anti or pro-proliferative effect but present more infiltrated immune cells (Beier et al., 2012). The tumor microenvironment is a well-known contributor to cancer progression. GBM’s tumor associated microglia/macrophages secrete TGFβ1 that binds to overexpressed TβRII at GICs surface, triggering the latter’s MMP9 release to promote tumor invasion (Ye et al., 2012).

Other Members of TGFβ Superfamily implicated in Glioblastoma biology

Even if TGFβ subfamily overwhelmingly drives GBM progression and is the subject of research focus, the other growth factors of the superfamily nevertheless play a role in this tumor’s biology. These growth factors, mainly BMPs, Activins, Nodal and GDFs regulate early vertebrate development and adult tissue maintenance but are also incriminated in some tumors development and metastasis (Wakefield and Hill, 2013). However, their effects on GBM evolution are antagonistic.

Bone morphogenetic proteins (BMPs)

In the BMPs canonical signaling, like in TGFβ pathway, R-SMADs (SMAD1, SMAD5 and SMAD8) are phosphorylated upon activation of BMP receptor of the serine/threonine family of membrane receptors. Activated R-SMADs form a complex with Co-SMAD (SMAD4) and the activated R-SMAD/Co-SMAD complex then translocates into the nucleus to activate BMPs transcriptional targets (Wrana, 2013). BMPs have diverse functions in embryonic brain development. For instance, BMPs trigger neuronal differentiation of precursors in the neocortical ventricular zone and promote astrogial lineage commitment of mammalian subventricular zone progenitor cells (Gross et al., 1996; Li et al., 1998). Neurogenesis in the adult brain is restricted to specific neurogenic regions located in the hippocampus, the subventricular zone, the striatum and the olfactory bulb (Ernst and Friesen, 2015). Along with their negative regulator Noggin, BMPs play an important regulatory role in neural stem cells niche (Lim et al., 2000).

Apart from their multiple roles in physiological processes in the brain, BMPs are involved in cancer biology. However, in contrast to TGFβ, BMPs have a tumor suppressor activity in GBM. Indeed, BMPs, especially BMP4, reduce GBM CD133+ cancer stem cell proliferation, induce their differentiation, and abolish their tumor formation and subsequent mortality in xenograft model (Piccirillo and Vescovi, 2006). This antitumor effect is mediated by the BMP/SMAD/SNAIL pathway (Savary et al., 2013).

Moreover, the resistance to temozolomide induced by GICs is suppressed by BMPs. High expression of O6-methylguanine-DNA-methyltransferase (MGMT) and hypoxia-inducible factor-1α (HIF-1α) is a common feature of GICs that generates resistance to temozolomide. BMP2 downregulates both MGMT and HIF-1α in GICs, leading to their differentiation and improving their sensitivity to temozolomide (Persano et al., 2012).

Because of their antitumor properties especially directed toward the GICs, BMPs are seen as attractive therapeutic tools that can allow to “cut the evil at its root”. For this purpose, nanocomplex encapsulation technique may be a good approach for BMP delivery to the target site (Reguera-Nuñez et al., 2014). However, cancer cells are not short of tricks. Indeed, certain tumor cells circumvent this phenomenon by producing BMPs antagonists such as Gremlin1 that inhibits the BMP’s canonical pathway and potentiate the tumor’s growth (Yan et al., 2014).

Nodal

In contrast to BMPs, Nodal promotes GBM cell growth. Nodal is essential for the induction of body axis during embryogenesis. Nodal triggers SMADs signaling pathway but also induces non-SMADs signaling such as extracellular-signal-regulated kinase (ERK) signal transduction pathway. Nodal, which is normally expressed in embryonic and reproductive cell types, is more and more described in tumor cells where it yields aggressive cancer phenotypes (Quail et al., 2013). GBM cells transfected with plasmid encoding Nodal show high proliferation rate upon activation of the Nodal receptors ALK4, ALK7 and SMAD3 phosphorylation (De Silva et al., 2012). Nodal stimulates tumor invasion by upregulating MMP2 and may also promote GICs via induction of LIF and Cripto-1 (Lee et al., 2010). In sum, Nodal promotes GBM cancer cells proliferation, invasion and may also support the stemness of GICs. Interestingly, TGFβ can enhance Nodal expression via ERK1/2 activation, to promote tumor proliferation and invasion, but inhibit apoptosis (Sun et al., 2014b).

Energy metabolism reprogramming is a well-known trick that cancer cells develop and constitute a hallmark of cancer (Hanahan and Weinberg, 2011). Albeit uneconomic energy wise, cancer cells commonly switch from the pyruvate pathway to glycolysis by upregulating HIF1α and HIF2α, leading to higher glucose uptake, low oxygen consumption and low mitochondrial metabolism. This process renders them more resistant to the hypoxic condition common in cancer. In GBM, Nodal triggers this metabolic switch by upregulating HIF1α (Lai et al., 2013).

However, Nodal tumor promotion is negatively regulated by Lefty, another member of the TGFβ superfamily. Indeed, Lefty inhibits Nodal expression, and impairs Nodal-induced expression of SMADs and activation of ERK1/2. It further inhibits cells proliferation and tumor invasion and enhances apoptosis (Sun et al., 2014a).

Activins

Activins are ubiquitous growth factors that regulate...
functions as diverse as gonadal function, hormonal homeostasis, growth and differentiation of musculoskeletal tissues, brain functions, proliferation and differentiation of embryonic stem cells and also cancer growth and metastasis (Tsuda et al., 2009). Activins bind to their serine-threonine kinase receptor to trigger SMAD signaling pathway and non-SMAD pathways including MAPK, PI3K/AKT and Wnt/β-catenin signaling (Tsuda et al., 2009). Activin A induced human GBM cells U87 proliferation via SMAD2/3 activation; this effect is negatively regulated by Follistatin that is an Activin-binding protein (Zhang et al., 2010).

Growth and differentiation factor (GDF)

GDF has been described to induce GBM progression. Indeed, GDF is found overexpressed in high-grade glioma where it yields an immune-escape function and correlates with poor patient survival. Likewise, GBM cells deprived of GDF become more vulnerable to natural killer cells (Roth et al., 2010). However, other sources suggest that GDF may be secreted by the tumor-infiltrating macrophages instead of the GBM tumor cells (Shnaper et al., 2009).

Crosstalk between TGFβ and Other Growth Factors in Glioblastoma

In GBM, as in cancer in general, signaling pathways usually overlap, creating cross-talks that eventually participate in the cancer’s trick to escape from endogenous repressions as well as exogenous threats represented by anti-cancer therapy. Thus, several pathways taken individually can lead to a same outcome, testifying to the redundancy of such a phenomenon. Considering GBM’s angiogenesis, TGFβ, PDGF-B and mostly HIF-1 can induce VEGF, the main contributor in this process. TGFβ can cooperate with both PDGF and EGF. Nonetheless, the interaction between TGFβ, PDGF and EGF is somewhat controversial. Indeed, some studies demonstrated that TGFβ can induce PDGF and EGF to promote GBM (Helseth et al., 1988; Bruna et al., 2007) while other evidence showed an inhibition of the same transcription factors by the TGFβ in some gliomas (Vergeli et al., 1995; Held-Feindt et al., 2003). The pleiotropic nature of TGFβ, whose effect is regulated by SMAD contextual partners may be a rational explanation for these differences.

Therapeutic Perspectives

In GBM, as in other cancers, the role of TGFβ subfamily is ambivalent. Initially protective, it switches later to promote the tumor progression. Differentiating when it protects from when it harms is of crucial importance. Shen et al. demonstrated that the epigenetic silencing of the tumor suppressor NDRG2 leads to TGFβ’s about-face in colon cancer while Xu et al. identified the adaptor protein 14-3-3ζ as the agent responsible for TGFβ’s wrong turn in breast cancer (Shen et al., 2014; Xu et al., 2015). The discovery of the causative agents of the same mechanism in GBM will be of unquestionable therapeutic importance.

Yet, several anti-TGFβ drugs have been developed even if the outcomes remain unsatisfactory (Table 1). Trabedersen, an antisense oligonucleotide of TGFβ, has been developed and successfully tested in phase I/II clinical trials (Hau et al., 2007). Trabedersen is a first-in-class gene silencing antisense compound (phosphorothioate oligodeoxynucleotide) designed to selectively downregulate the production of TGFβ2 at the translational level. A phase III clinical trial initiated in September 2008 was stopped in March 2012 owing to neurosurgical procedures and first-line standard of care for patients that made impossible to recruit the projected number of patients (Akhurst and Hata, 2012).

Additionally, inhibitors of integrin receptors have been found therapeutically relevant in GBM. Integrins are involved in TGFβ activation by mechanical pulling of the large latent complex (Horiguchi et al., 2012). When treated with integrin inhibitors, glioma cells undergo atypical cell death in combination of anoikis, apoptosis and necrosis, which can be rescued by TGFβ treatment (Silginer et al., 2014). Cilengitide is an antiangiogenic small molecule, an inhibitor of αvβ3 and αvβ5 integrin, that prevents TGFβ’s tumor promotion in glioma cells by decreasing TGFβ level and dephosphorylating SMAD2 (Roth et al., 2013). After promising results in animal models (Mikkelsen et al., 2009), this molecule has been translated to clinical trials with as-yet unsatisfactory results (Stupp et al., 2008; Eisele et al., 2014).

Blocking the abnormal signal at its origin by inhibiting TGFβ receptor is another strategy to prevent its harmful effect. Thus, small molecules have been employed against TβRs. However, these small molecules are subject to nonspecific binding with resultant “off-target” effects. Galunisertib (LY2157299) is an example tested in phase Ib/IIa clinical trials (Akhurst and Hata, 2012; Katz et al., 2013).

In contrast, antibodies offer a more targeted approach in anti-TGFβ based therapy. Fresolimumab is a human monoclonal antibody that can neutralize all TGFβ’s isoforms with high-affinity in several cancer cell lines. This antitumor property led to its clinical translation in several cancers including GBM, malignant melanoma and renal cell carcinoma attesting to its safety and potential therapeutic effect (Morris et al., 2014). Nonetheless, fresolimumab can induce skin lesions, which require caution (Lacouture et al., 2015). Efficient drug delivery is an important aspect of cancer treatment, especially in the brain, which is protected by the blood-brain barrier. Recently, den Hollander et al. demonstrated a satisfactory uptake of fresolimumab by high-grade glioma cells, yet with no clinical outcome. (den Hollander et al., 2015). Further investigation should provide more insight as to the efficacy of this drug in GBM.

Conclusion

In sum, the involvement of the TGFβ superfamily in GBM biology is multidimensional. The TGFβ subfamily orchestrates complex events involving cancer cell proliferation and migration, immune suppression, angiogenesis, mesenchymal phenotype induction and
References


Ashley DM, Kong FM, Bigner DD, et al (2012). Heterogeneity and functions underlie the aggressive phenotypes exhibited by tumors with high level of TGFβ and justifies the need to target this growth factor for drug development. In the same way, Nodal, Activin and GDF promote GBM progression, whereas BMPs and Lefty, by targeting GICs and nodal respectively, impair GBM growth.

Acknowledgements

We would like to thank Jorie Larson MPH for her contribution in proofreading this paper. This work was supported by Taipei Medical University (TMU104-AE2-102-4) and Comprehensive Cancer Center of Taipei Medical University (MOHW104-TDU-B-212-124-001) funded by Health and welfare surcharge of tobacco products.

...


Schaffner F, Ray AM, Donentwill M (2013). Integrin α5β1, the fibronectin receptor, as a pertinent therapeutic target in solid tumors. Cancers, 5, 27-47.


Overview of Transforming Growth Factor β Superfamily Involvement in Glioblastoma Initiation and Progression


DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.6813